Company / Cash & Equivalents
ImmunityBio, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$88.3M
FY2025
5-year range
$34.9M / $265.5M
FY2021-FY2025
Trend
-38.4%
vs FY2024
Sector context
#150 of 207
Health Care
What the data says
At $88M, ImmunityBio, Inc.'s cash & equivalents ranks #150 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $8M in FY2017 to $265M in FY2023.
Based on SEC 10-K filings.
$88M in FY2025 with a 5-year CAGR of +20.4%.
Declined from $265M to $88M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.5%
- 5-Year CAGR
- +20.4%
- 10-Year CAGR
- -
Sector benchmark
#150 of 207 in Health CareTop 72% of 207This company $88.3M Sector average $669.5M
▼
-86.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 38.4% year-over-year.
- Ranks #150 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $88.3M | -38.4% |
| FY2024 | $143.4M | -46.0% |
| FY2023 | $265.5M | +153.7% |
| FY2022 | $104.6M | +199.7% |
| FY2021 | $34.9M | +0.0% |
| FY2020 | $34.9M | -53.9% |
| FY2019 | $75.8M | +217.5% |
| FY2018 | $23.9M | +195.3% |
| FY2017 | $8.1M | -86.3% |
| FY2016 | $59.1M | -66.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026